CONVENING NOTICE This is the convening notice for the 2023 annual general meeting of shareholders of InflaRx N.V. to be held on April 26, 2023. | April 5, 2023
Changes in governance with the appointment of a new Chairman of the Board of Directors and a new Director Regrouping of all French Advicenne's teams in the new Paris headquarters to optimize
Orphan drug firm Sobi opens new European base pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook
Regulatory News:
Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC), a French company specialized in the development of therapeutic products adapted to children and adults for treating nephrological and neurological orphan diseases, today reported its 2020 financial results.
2020 HIGHLIGHTS
Scientific developments
On March 10, 2020, Advicenne was authorized to make ADV7103 available within the framework of a Temporary Authorization for Use (TAU) scheme established by France s National Agency of Medicine and Health Products Safety (
Agence nationale de sécurité du médicament et des produits de santé (ANSM)). This authorization allows the exceptional use of coated 8 mEq and 24 mEq granules in sachets for the treatment of distal renal tubular acidosis (dRTA) in France. Its prescription is reserved for physicians specializing in nephrology.